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ABSTRACT
Shivering related with spinal anesthesia commonly occurs in patients. It is not only uncomfortable
for the patients, but also related to some complication. The efficacy of pethidine in the prevention
of shivering is well known. The aim of this study was to compare the efficacy of intrathecal
pethidine 0.1 mg/kg body weight (BW) and 0.2 mg/kg BW as shivering-prevention drug after
spinal anesthesia. This was a randomized, double-blind controlled trial study involving 196
subjects between the age 18-40 years with ASA physical status I-II, gestional age 37-42 weeks,
BW of 40-70 kg or Body Mass Index (BMI) <30 kg/m2, body height >145 cm who underwent a
caesarean delivery section with spinal anesthesia based of World Health Organization (WHO)
procedure in cesarean delivery in Dr. Sardjito General Hospital, Yogyakarta and affiliated hospital.
Subjects were divided into two groups with 98 subjects of each group. Group A was given an
hyperbaric 0.5% bupivacaine 10 mg and pethidine 0.1 mg/kg BW, and Group B was given an
hyperbaric 0.5% bupivacaine 10 mg and pethidine 0.2 mg/kg BW in the same volume (2.5 mL).
The seubjects were observed for the incidence and severity of shivering and side effects of
pehtidine. The results showed that the incidence of shivering in Group A (35.70%) was significantly
greater than in Group B (22.44%) (p<0.05). However, the onzet an duration of shivering were
not significantly different in both groups (p>0.05). Moreover, the incidence of nausea and
vomiting in Group A (8.33%) was significantly lower than Group B (22.45%). In conclusion,
pethidine 0.2 mg/kg BW is more effective to preven shivering than pethidine 0.1 mg/kg BW
although the incidence of its side effects is more higher.
ABSTRAK
Shivering akibat tindakan anestesi spinal umum terjadi pada pasien. Kejadian ini tidak hanya
membuat rasa tidak enak pasien tetapi juga berkaitn dengan berbagai komplikasi yang ditimbulkan.
Efikasi petidin dalam mencegah sudah dikenal luas. Penelitian ini bertujuan untuk membandingkan
daya guna petidin intratekal 0,1 mg/kg berat badan (BB) dengan 0,2 mg/kg BB sabagai obat
untuk mencegah shivering setelah anestesi spinal. Penelitian ini merupakan uji klinik acak tersamar
ganda yang melibatkan 196 subjek berumur antara 18-40 tahun, dengan status fisik ASA I-II,
umur kehamilan 37-42 weeks, BB 40-70 kg atau Indeks Masa Tubuh (IMT) <30 kg/m2, tinggi
badan >145 cm yang menjalani bedah cesar dengan anestesi spinal sesuai dengan prosedur
WHO. Subjek dibagi menjadi 2 kelompok dengan masing-masing kelompok 98 subjeks. Kelompok
A diberi 10 mg bupivakain 0,5% dan petidin 0,1 mg/kg BB dan Kelompok B diberi 10 mg
bupivakain 0,5% dan petidin 0,2 mg/kg BB dengan volume sama (2,5 mL). Subject diamati
terhadap kejadian dan keparahan terjadinya shivering dan efek samping akibat petidin. Hasil
penelitian menunjukkan kejadian shivering pada Kelompok A (35,7%) secara nyata lebih tinggi
dari pada Kelompok B (22,4%) (p<0.05). Namun demikain onset dan lama terjadinya shivering
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tidak berbeda secara nyata antara kedua kelompok (p>0,05). Selain itu, kejadian mual dan
mutah pada Kelompok A (8,33%) lebih rendah dibandingkan Kelompok B (22,45%). Dapat
disimpulkan bahwa petidin 0,2 mg/kg BB lebih berdaya guna dalam mencegah shivering daripada
petidin 0,1 mg/kg BB meskipun kejadian efek sampingnya lebih tinggi.
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INTRODUCTION
The incidence of shivering post regional
anesthesia in section action caesarian is about
85%. Shivering is an event that can provide the
adverse implications for patient.1 Peripheral
inhibition is a major cause of hypothermia
during regional anesthesia.2 Side effects are said
to occur in the form of shivering when oxygen
consumption increases by 400%, as well as the
increase in blood pressure, intracranial pressure
and intraocular pressure, cardiac output and
minute ventilation and metabolic rate up to 200-
500%, oxygen saturation of mixed vein
reduction.3
Pharmacological approaches have
implemented to prevent shivering.Awide range
of drugs have been used to prevent shivering
including pethidine. Intrathecal pethidine in
varying dose of 10-50 mg has long been used to
prevent and reduce shivering.1,4-7 At usual dose,
pethidine does not cause severe side effects in
both mothers and infants such as respiratory
depression, however the incidence of nausea
and vomiting remains occur. Booth et al.8
reported that although pethidine could
potentially prolong analgesia during labor, it use
was associated with a significant incidence of
nausea or vomiting.
Prevention of shivering in patietns
undergoing caesarean surgery is important.
Although pethidine is remarkably effective to
prevent shivering, its side effect is often
reported. The side effects of pethidine is usually
dose-dependent.1 In addition, this side effects
are influenced by some factors including
physiological changes associated with
pregnancy. This study was conducted to
obtained the optimal dose of pethidine that
effectively can prevent shivering with minimaly
side effects. The usual dose of pethidine which
used as an adjuvant local anesthetic drug is 0.2
mg/kg BW. In this study, this pethidine dose of
0.2 mg/kg BW was compared to 0.1 mg/kg BW
in 0.5% hyperbaric bupivacaine 10 mg in order
to obtain the optimal efficacy with minimal sife
effects.
MATERIALS AND METHODS
Subjects
This was a randomized, double-blind
controlled trial study involving 196 subjects
between the age 18-40 years withASAphysical
status I-II, gestional age 37-42 weeks, BW of
40-70 kg or Body Mass Index (BMI) <30 kg/
m2, body height >145 cm who underwent a
caesarean delivery section with spinal
anesthesia based of World Health Organization
(WHO) procedure in cesarean delivery in Dr.
Sardjito General Hospital, Yogyakarta and
affiliated hospitals i.e. Dr. Soeradji General
Hospital, Klaten, Banyumas District Hospital,
Purworejo District Hospital, Cilacap District
Hospital. Subjects were divided into two groups
with 98 subjects of each group. Group A was
given an hyperbaric 0.5% bupivacaine 10 mg
and pethidine 0.1 mg/kg BW, and Group B was
given an hyperbaric 0.5% bupivacaine 10 mg
and pethidine 0.2 mg/kg BW in the same volume
(2.5 mL). Exclusion criteria included patients
or families refusing to participate in the study,
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having a history of allergy to bupivacaine,
pethidine, ketorolac, and metoclopramide,
having initial body temperature >38 oC or <36
oC, having a history of hypertension with systolic
blood pressure (TDS)/diastolic blood pressure
(TDD) e” 140/90 mmHg, having an hepatic and
renal dysfunction, drinking drugs inhibiting
monoamine inhibitor, and having
contraindication to spinal anesthesia. The study
has been approved by the Medical and Health
Research Ethic Committee, Faculty of
Medicine, Universitas Gadjah Mada,
Yogyakarta.
Protocol of study
Preoperative visit and checkup were
performed before surgery and characteristics of
patients were taken. A detail operating
procedure conducting was explained to all
patients. The patients who met the inclusion and
exclusion criteria and were willing to be
involved in the study would signed an inform
consent. The patient was then placed in the
surgery preparation room and an intravenous
line was installed using abbocath 18G on the
dorsum manus vein of the hand and 500 mL of
Ringer’s lactate solution was infused at dosage
of 2 cc/kg BW/hour for 30 minutes. Operating
room temperature was maintained at 22-24 oC.
After shifting the patients to operation table,
preoperative vital parameters like body
temperature, blood pressure, mean arterial
pressure (MAP), heart rate (HR) and SpO2 rate
were monitored and recorded prior to the
anesthetic procedure. A few minutes before
spinal anesthesia, pethidine 0.2 or 0.1 mg/kg
BW was injected as an intravenous bolus
injection. The patient was then placed in sitting
position and spinal anesthesia was conducted
at the lumbar intervertebral spaces 3-4 using
10 mg of 0.5% hyperbaric bupivacaine with a
25 G needle size spinoken under sterile
technique. The patients were then placed in the
modified supine position with a pillow. The
level of sensory blockade was evaluated using
pinprick method at the second minute after spinal
induction and continued in five-minute interval
for 20 minutes. Standards for patient
hemodynamic monitoring during anesthesia i.e.
blood pressure, PR and respiratory rate (RR)
was performed in two-minute interval until the
baby born and continued in five-minute interval
until the end of the operation. The incidence,
severity, onzed and duration of shivering as well
as the side effect of drugs were observed during
surgery conducted until four hours after spinal
anesthesia. The severity of shivering was
measured as previous performed by Crossley
and Mahajan9 with criteria as follow: Grade 0
if no shivering was observed; Grade 1 if subject
experienced piloerection or peripheral
vasoconstriction, shivering invisible; Grade 2
if subject experienced no muscle activity, but
limited to one muscle group; Grade 3 if subject
experience muscular activity occurring in more
than one muscle group; Grade 4 if subject
experienced shivering in the whole body.
Subjects were considered to experience
shivering if they have no shivering, whereas
subjects were considered to experience
shivering if they have shivering of Grade 1-4.
Subjects who had shivering of Grade 1-2, non-
pharmacological intervention (heating) would
be conducted. Whereas, subjects who had
shivering of Grade 3-4, pethidine 25 mg or other
antishivering agents such as ketamine, tramadol
or clonidine would be administered. Moreover,
subjects who experienced an adverse effects due
to spinal anesthesia or dugs administered,
pharmacological intervention would be
conducted. Intravenously ephedrine 10 mg
would be given for hypotension, intravenously
metoclopramide 10 mg for nausea and vomiting
or other antiemetic agents if not cure with
metoclopramide, naloxone 0.17-2 µg/kg BW/
hour for pruritus and oxygenation with naloxone
0.4-2 mg for respiratory depression.
190
J Med Sci, Volume 45, No. 4, Desember 2013: 187-195
Statistical analysis
Data were tabulated and presented as mean
± standard deviation (SD) or percent. Data of
age, body weight, body height, BMI, body
temperature, blood pressure, MAP, physical
status, height of block, duration of operation,
hemodynamic chages, operation room
temperature were analyzed statistically using
independent t-test or Mann-Whitney U test. Data
of incidence and severity of shivering and the
side effects of pethidine were analyzed
statistically using Chi square test. A p value
<0.05 was considerd statistically significant.
RESULTS
The characteristics of patients of both
groups are presented in TABLE 1. No significant
difference was observed in terms of age, weight,
BMI, body temperature, operation room
temperature, diastolic blood pressure, MAP,
physical status, height of block and duration of
operation in both groups (p>0.05). However,
significant difference was observed in body
height and systolic blood pressure of both groups
(p<0.05).
TABLE 1. Characteristics of subjects (mean ± SD or percent) in both group
191
Kusumasari et al., Efficacy of pethidine 0.1 and 0.2 mg/kg body weight as an adjuvant
of intrathecal bupivacaine 0.5% 10 mg in preventing shivering
Changes in MAP dan body temperature
before, during and after spinal anesthesia as well
as amount and types fluid used during surgey
are presented in TABLE 2. No significant
difference was observed in MAP and body
temperature before, during as well as after
surgery (p>0.05). In addition, the number and
type of fluid used during surgery were not also
significantly different in both groups (p> 0.05).
TABLE 2. Changes in MAP dan body temperature before, during and after spinal
anesthesia and amount and types fluid used
The incidence, severity, onzet and duration
of shivering after spinal anesthesi in Group A
compare to Group B are presented in TABLE
3. The incidence of shivering in Group A (35
incident or 35.70%) was significantly higher
than in Group B (22 incident or 22.44%)
(p<0.05). However, the onzet an duration of
shivering were not significantly different in
group ( (p>0.05). The onzet of shivering in
Group A and B were 31.7±11.61 minutes and
34.31±8.76 minutes, respectively. While the
duration of shivering in Group A and B were
3.97±1.10 minutes and 3.90±1.30 minutes,
respectively. Among 24 subjects who had
experienced shivering in Grade 1-2 and
provided non-pharmacological intervention
with giving blankets, only 15 subjects could be
cured. Nine subjects who no cure, intravenous
bolus pethidine 25 mg were given. Whereas 33
subjects who had experienced shivering in
Grade 3-4, non-pharmacological intervention as
well as pharmacological intervention using
intravenous bolus pethidine 25 mg or tramadol
25 were conducted. The incident of persistent
shivering requiring the addition of other
antishivering was not observed.
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TABLE 3. Incidence, severity, onzet and duration of shivering after spinal
anesthesi in both groups
The incidence of side effects after spinal
anesthesi in both groups are presented in
TABLE 4. The incidence of nausea and vomiting
in Group A receiving pethidine 0.1 mg/kg BW
(8.33%) was significantly lower than Group B
receiving pethidine 0.2 mg/kg BW (22.45%).
The incident of pruritus and respiratory
depression in both groups were not observed
in both groups in this study.
TABLE 4. The incidence of side effects after spinal anesthesi in both groups
DISCUSSION
In general, the characteristicts of subjects
in both groups were not significantly different,
except the body height which was shorter in
GroupA compare to Group B. The body height
is one of the factors that influences the height of
the block on spinal anesthesia.10 However, this
study showed the body height of subjects did
not affect the height of the block that could lead
to shivering. It was indicated that the subjects
of the two groups were comparable. Some
factors have been reported could influence the
shivering. Operation room temperature and
infusion rate at temperature of a cool room can
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decrease of core temperature of the body. In
addition, wide and duration of open exposure
of operation site can increase heat loss of skin
that causes the difference between core
temperature and peripheral temperature of the
body and leads to the shivering.11 In this study,
factors that contribute the incidence of shivering
have been controlled. Gender, type of operation,
height of block, operation room temperature,
duration of operation, body temperature, and
amount of liquid used that influence the shivering
in the both group of this study were not
significantly difference. Therefore, the
incidence of shivering observed in this study
was only influenced by the dose of pethidine
administration.
The incidence of shivering in GroupAwho
given the pethidine 0.1 mg/kg BW (35.71%)
was significantly higher (p<0.05) than Group
B who given the pethidine 0.2 mg/kg BW
(22.44%). The incidence of shivering in this
study was lower that it was reported in the
previous studies that range from 56-85%.4,1 The
different in the incidence of shivering may be
caused by the difference of the characteristicts
of subjects and research methods used. In the
previous study, the operation room temperature
was maintained between 21 to 23 oC, whreas
in this study the temperature was maintained
between 22 to 24 oC. In addition, the height of
block achieved in previous study (T8-C2)1 was
relatively higher than this study (T4-6). The
height of the block is directly associated with
the decrease of shivering threshold. The higher
the spinal block can decrease the shivering
threshold.11 Unfortunately, the liquid used during
surgery that can influence the incidence of
shivering was not repoted in the previous
study.1
The effect of intrathecal phetidine in
preventing shivering has been proven by some
authors.1,4-7 However, its mechanism of action
can not be clearly explained. The antishivering
effect of pethidine may due to its effects on
spinal cord ê-opioid receptors and shivering
threshold temperature. Nevertheless, these
effects are almost impossible to achieve through
the systemic absorption of intrathecal phetidine
ingestion.2,1
The pethidine plasma levels as anti-
shivering ranges from 0.6 to 1.8 µg/mL that
achieved after intravenously administration.12
In intrathecal administration, the pethidine
plasma levesl is lower due to systemic absorp-
tion effects. It could explain the high incidence
of shivering after intrathecal pethidine
administration at dose of 0.1 mg/kg BW.
Pethidine plasma levels of 107 ± 20 ng/mL are
achieved after intrathecal pethidine administrat-
ion at dose of 1 mg/kg BW. This dose is five
time higher than pethidine dose needed for
prevention of shivering (0.2 mg/kg BW).13,1 The
effects of antishivering obtained after intrathecal
pethidine 0.1 and 0.2 mg/kg BW may due to
stimulation of ê-opioid receptors on the spinal
cord. The antishivering effect reduces with
reduction of the pethidine dose from 0.2 to 0.1
mg/kg BW. In addition, pethidine plays role as
N-methyl-D -aspartate (NMDA) receptor
antagonist14 where the receptor can also be found
in the spinal cord. Inhibition of the NMDA
receptor increases antishivering effect of the
pethidine.
This study found that the incidence of nausea
and vomiting after intrathecal pethidine
administration at dose of 0.1 mg/kg BW (8.33%)
was significantly lower than at dose of 0.2 mg/
kg BW (22.45%). This result is consistent with
the previous studies that reported the incidence
of nausea and vomiting ranged from 30-60% in
the subjects who received intrathecal
pethidine.4,7,15
The incidence of nausea and vomiting are
about 20% in subjects who underwent spinal
anesthesia. The risk factors that are associated
with nausea and vomiting including high of block
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more than T5, hypotension, opioid
administration, and history of motion sickness.16
Nausea and vomiting caused by intrathecal
administration of opioid drugs due to
distribution of the drug to sefalad in
cerebrospinal fluid lead to interaction with
opioid receptors in the postrema area.
Sensitization of vestibular system as well as
slowing gastric emptying movement due to
opioid drugs also plays a role in causing the
nausea and vomiting.17 The nausea and vomiting
observed in this study may be caused by the
intrathecal pethidine administration. However,
other risk factors may also contribute in the
incidence of the nausea and vomiting. The side
effects of pruritus and respiratory depression
were not observed in this study. The respiratory
depression has been reported in the previous
study after intrathecal pethidine administration
at doses more than 50 mg or doses for
sedation.18,19 In this study, doses of pethidine is
relatively small i.e. 0.1 and 0.2 mg/kg BW.
Therefore, the adverse effects of respiratory
depression have not been observed, yet.
The characteristics of operation room of
the five hospitals where the study conducted was
also different especially in the terms of area,
number of personel in the operation room,
lighting ect. However, the factors that influnced
the clinical outcome such as the operation room
temperature were controlled by maintaining the
temperature between 22-24 oC.
CONCLUSION
In conclusion, intrathecal pethidine at doses
of 0.2 mg/kg BW is more effective to preven
shivering in subjects who undergo spinal
anesthesia than at dose of 0.1 mg/kg BW.
However, the incidence of nausea and vomiting
of the pethidine at dose of 0.2 mg/kg BW is
more higher than at dose of 0.1 mg/kg BW.
Further researchs are needed to obtain the
optimal doses of intrathecal pethidine to prevent
shivering post spinal anesthesia.
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